Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Holding LTRN?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.51Last Year’s EPS
-$0.39Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -8.04%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in AI-driven drug development, regulatory achievements, and strategic trial expansions, while noting increased financial losses and R&D expenses. The positive advancements and strategic positioning outweigh the financial challenges.Company Guidance
During Lantern Pharma's Q3 2024 earnings call, the guidance provided highlighted several key metrics and achievements. The company reported a net loss of approximately $4.5 million, or $0.42 per share, compared to $3.2 million or $0.29 per share for the same quarter in 2023. R&D expenses were up, reaching $3.7 million from $2.2 million the previous year, driven by increased clinical trial activity. The company closed the quarter with $28.1 million in cash, providing a cash runway into late 2025. Their AI-driven RADR platform has enabled the advancement of 14 drug programs, including three precision oncology drug candidates in clinical trials. Notably, Lantern's HARMONIC trial showed an 86% clinical benefit rate in its first seven patients, leading to plans for expansion in Asia. Additionally, LP-184 received FDA Fast Track designation for glioblastoma, and the company secured three new FDA rare pediatric designations. Lantern's strategic focus on AI-driven drug development aims to transform cancer treatment while maintaining capital efficiency and targeting significant returns for investors.AI-Driven Drug Development Progress
Lantern Pharma's RADR AI platform has enabled the advancement of 14 drug programs since 2020, with significant clinical progress in Phase 2 HARMONIC trial and Phase 1 programs for LP-184 and LP-284.
FDA Fast Track Designation
LP-184 received FDA Fast Track designation for glioblastoma, providing potential opportunities to expedite development.
HARMONIC Trial Expansion
Expansion of the HARMONIC trial into Asia with 10 sites in Japan and Taiwan to address high prevalence of never smoker lung cancer.
Strong Financial Position
Lantern closed the quarter with $28.1 million in cash, providing a runway into late 2025.
Scientific Advisory Board for Starlight Therapeutics
Formation of a distinguished advisory board for CNS and brain cancer-focused subsidiary, Starlight Therapeutics.
FDA Rare Pediatric Designations
Received three new FDA rare pediatric designations for LP-184, increasing potential for priority review vouchers.
---
LTRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LTRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $3.42 | $3.84 | +12.28% |
| Aug 08, 2024 | $4.23 | $3.90 | -7.80% |
| May 09, 2024 | $6.81 | $6.16 | -9.54% |
| Mar 18, 2024 | $9.96 | $7.49 | -24.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lantern Pharma, Inc. (LTRN) report earnings?
Lantern Pharma, Inc. (LTRN) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Lantern Pharma, Inc. (LTRN) earnings time?
Lantern Pharma, Inc. (LTRN) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LTRN EPS forecast?
LTRN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.51.
---